SCHEMBL4554346

SCHEMBL4554346

CCOC(=O)c1nn(-c2ccccc2)cc1C

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.77
RAB9A P51151 6/20 0.77
ALDH1A1 P00352 5/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
NPSR1 Q6W5P4 3/20 0.62
GLA P06280 1/20 0.62
NFKB1 P19838 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62
POLB P06746 1/20 0.58
KDM4E B2RXH2 3/20 0.58
LMNA P02545 1/20 0.58
MAPK1 P28482 1/20 0.56
DGAT1 O75907 1/20 0.56
DRD4 P21917 1/20 0.55
TP53 P04637 1/20 0.55
ALOX12 P18054 1/20 0.55
CHEK1 O14757 1/20 0.55
EGFR P00533 1/20 0.55
KDR P35968 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28351543 0.90 NPC1 (0.71) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL14019455 0.88 NPC1 (0.77) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL14019454 0.86 NPC1 (0.69) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL20795066 0.86 NPC1 (0.78) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL14141391 0.86 NPC1 (0.73) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL718420 0.85 NPC1 (0.60) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL5804153 0.84 NPC1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL18039628 0.84 NPC1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL718714 0.84 NPC1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL16635022 0.82 NPC1 (0.58) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9226505-B2 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 US disclosed
EP-2753604-B1 PDE10 MODULATORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-20140329684-A1 USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-11-06 US disclosed
US-8772510-B2 PDE10 modulators HOFFMANN-LA ROCHE INC. (US) 2014-07-08 US disclosed
WO-2013034506-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-14 WO disclosed
US-20130059833-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
EP-2044055-A2 AMIDE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-08 EP disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
EP-1633348-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Elan Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
WO-2004098589-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329684-A1 USE OF 4-SUBSTITUTED 1-PHENYLPYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGENTS AGAINST ABIOTIC PLANT STRESS HPD, HSF1, PDK4 NPC1 3861/4885RAB9A 3344/4885ALDH1A1 139/4885
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 NPC1 214/4885RAB9A 2100/4885ALDH1A1 231/4885
US-20130059833-A1 PDE10 MODULATORS PDE10A, PDE5A, PDE2A NPC1 2474/4885RAB9A 109/4885ALDH1A1 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.